Nara, Japan

Mitsuhiro Okamoto

This inventor holds 1 USPTO granted patent. Top assignee: Shionogi Company Limited. Active years: 1990.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mitsuhiro Okamoto. Retrieved from https://idiyas.com/inventor/mitsuhiro-okamoto-0cc69uky

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 1990

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mitsuhiro Okamoto: Innovator in Monoclonal Antibody Research

Introduction

Mitsuhiro Okamoto is a prominent inventor based in Nara, Japan. He is known for his significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies.

Latest Patents

Mitsuhiro Okamoto holds a patent for a monoclonal antibody specific to human pancreatic phospholipase A.sub.2. This invention relates to monoclonal antibodies that exhibit high affinity to human pancreatic PLA.sub.2, along with the production methods, hybridomas that produce them, and an immunoassay for human pancreatic PLA.sub.2 utilizing these antibodies. He has 1 patent to his name.

Career Highlights

Okamoto is associated with Shionogi & Company Limited, a well-respected pharmaceutical company. His work has contributed to advancements in medical diagnostics and therapeutic applications.

Collaborations

He has collaborated with notable colleagues, including Atsushi Misaki and Masao Kono, to further enhance research and development in his field.

Conclusion

Mitsuhiro Okamoto's innovative work in monoclonal antibodies showcases his dedication to advancing medical science. His contributions are vital for future developments in diagnostics and treatment options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…